Drugs / Peginterferon-α2a

Trials 4 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 22 trials
Phase 2 NCT02175966 Jul 2014 → Jan 2015 hepatitis C virus infection Bristol-Myers Squibb Completed No outcome recorded
Phase 2 NCT01463956 Jan 2012 → Jun 2014 chronic hepatitis C virus infection, cirrhosis of liver French National Agency for Research on AIDS and Viral Hepatitis Completed No outcome recorded
Phase 42 trials
Phase 4 NCT01277601 Apr 2011 → Aug 2014 chronic hepatitis B virus infection Gilead Sciences Completed No outcome recorded
Phase 4 NCT00881582 Jan 2009 → Dec 2011 chronic hepatitis C virus infection King Abdulaziz Medical City Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT02381379 Comparator Mar 2015 → Oct 2018 chronic myeloid leukemia Ministry of Health, Malaysia Unknown No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Peginterferon-α2a “Patients chronically infected with the hepatitis B virus rarely achieve loss of serum hepatitis B surface antigen (HBsAg) with the standard of care. We evaluated HBsAg loss in...” PMID 26453773 Oct 2015
4

“Safety and efficacy of peginterferon-α2a plus ribavirin treatment in renal transplant recipients with chronic hepatitis C.” PMID 23428875 Feb 2013

NCT01463956

NCT02175966

NCT02381379

Known as PEG-interferon alfa-2a PEG-interferon alfa-2a and ribavirin.” NCT00881582
Known as PegIFNα-2a “We assessed the safety and efficacy of PegIFNα-2a and ribavirin (RBV) combination therapy in HCV-infected RT recipients.” PMID 23428875 Feb 2013
Known as Pegylated interferon alfa-2a Pegylated interferon alfa-2a - standard dose; plus ribavirin - standard dose” NCT00881582
Route Subcutaneous “Peg-IFN 180 µg administered via subcutaneous injection once weekly” NCT01277601